Search research articles
Contact Us
Filters
Showing results (31-40 of 103) with videos related to
Page
of 11
Sort By:
Cancer Chemotherapy and Pharmacology
|
August 7, 2008
A phase I and pharmacokinetic study of paclitaxel poliglumex and cisplatin in patients with advanced solid tumors
Claire F Verschraegen, Keith Skubitz, Adil Daud, et al.
Pigment Cell & Melanoma Research
|
September 19, 2017
Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS-mutant and wild-type melanoma
Alain P Algazi, Rosaura Esteve-Puig, Adi Nosrati, et al.
British Journal of Cancer
|
January 20, 2017
Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma
Adil Daud, Harriet M Kluger, Razelle Kurzrock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 20, 2005
Phase II trial of karenitecin in patients with malignant melanoma: clinical and translational study
Adil Daud, Nikola Valkov, Barbara Centeno, et al.
Advances in Radiation Oncology
|
September 6, 2021
Should Sentinel Lymph Node Biopsy Status Guide Adjuvant Radiation Therapy in Patients With Merkel Cell Carcinoma?
Tessnim R Ahmad, Harish N Vasudevan, Ann A Lazar, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
September 16, 2010
Changes in dendritic cell phenotype after a new high-dose weekly schedule of interleukin-2 therapy for kidney cancer and melanoma
Steven E Finkelstein, Timothy Carey, Ingo Fricke, et al.
Annals of Surgical Oncology
|
January 2, 2007
Down-regulation of pro-apoptotic genes is an early event in the progression of malignant melanoma
Eric H Jensen, James M Lewis, James M McLoughlin, et al.
Journal of the American Academy of Dermatology
|
December 3, 2014
Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma
Martina Sanlorenzo, Aditi Choudhry, Igor Vujic, et al.
Journal of Surgical Oncology
|
April 12, 2011
Cutaneous melanoma: a model to study cancer metastasis
Stanley P L Leong, Jeffrey E Gershenwald, Seng-Jaw Soong, et al.
Nature Reviews. Cancer
|
August 29, 2019
An analysis of genetic heterogeneity in untreated cancers
Johannes G Reiter, Marina Baretti, Jeffrey M Gerold, et al.
Page
of 11
Search research articles
Search
Showing results (31-40 of 103) with videos related to
Sort By:
Page
of 11
Cancer Chemotherapy and Pharmacology
|
August 7, 2008
A phase I and pharmacokinetic study of paclitaxel poliglumex and cisplatin in patients with advanced solid tumors
Claire F Verschraegen, Keith Skubitz, Adil Daud, et al.
Pigment Cell & Melanoma Research
|
September 19, 2017
Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS-mutant and wild-type melanoma
Alain P Algazi, Rosaura Esteve-Puig, Adi Nosrati, et al.
British Journal of Cancer
|
January 20, 2017
Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma
Adil Daud, Harriet M Kluger, Razelle Kurzrock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 20, 2005
Phase II trial of karenitecin in patients with malignant melanoma: clinical and translational study
Adil Daud, Nikola Valkov, Barbara Centeno, et al.
Advances in Radiation Oncology
|
September 6, 2021
Should Sentinel Lymph Node Biopsy Status Guide Adjuvant Radiation Therapy in Patients With Merkel Cell Carcinoma?
Tessnim R Ahmad, Harish N Vasudevan, Ann A Lazar, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
September 16, 2010
Changes in dendritic cell phenotype after a new high-dose weekly schedule of interleukin-2 therapy for kidney cancer and melanoma
Steven E Finkelstein, Timothy Carey, Ingo Fricke, et al.
Annals of Surgical Oncology
|
January 2, 2007
Down-regulation of pro-apoptotic genes is an early event in the progression of malignant melanoma
Eric H Jensen, James M Lewis, James M McLoughlin, et al.
Journal of the American Academy of Dermatology
|
December 3, 2014
Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma
Martina Sanlorenzo, Aditi Choudhry, Igor Vujic, et al.
Journal of Surgical Oncology
|
April 12, 2011
Cutaneous melanoma: a model to study cancer metastasis
Stanley P L Leong, Jeffrey E Gershenwald, Seng-Jaw Soong, et al.
Nature Reviews. Cancer
|
August 29, 2019
An analysis of genetic heterogeneity in untreated cancers
Johannes G Reiter, Marina Baretti, Jeffrey M Gerold, et al.
Page
of 11